ACSM Certified Exercise Physiologist - DOMAIN 1 ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Exam with verified detailed solutions ||\\//|| ||\\//|| ||\\//|| ||\\//||
Pre-activity screening procedures and tools that provide accurate information about the ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
individual's health/medical history, current medical conditions, risk factors, ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
signs/symptoms of disease, current physical activity habits, and medications ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
1. Self-guided methods such as the Physical Activity Readiness Questionnaire (PAR-Q) or
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
the modified AHA/ACSM Health/Fitness Facility Preparticipation Screening Questionnaire.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
2. CVD risk factor assessment and classification by qualified health/fitness, clinical exercise,
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or health care professionals
||\\//|| ||\\//|| ||\\//|| ||\\//||
3. Medical evaluation including a physical examination and stress test by a qualified health
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
care provider. ||\\//||
The key components included in informed consent
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Informed Consent: ||\\//||
1. Purpose and explanation of the test
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
2. Attendant risks and discomforts
||\\//|| ||\\//|| ||\\//|| ||\\//||
3. Responsibilities of the participant
||\\//|| ||\\//|| ||\\//|| ||\\//||
4. Benefits to be expected
||\\//|| ||\\//|| ||\\//|| ||\\//||
5. Inquiries
||\\//||
6. Use of medical records
||\\//|| ||\\//|| ||\\//|| ||\\//||
7. Freedom of consent
||\\//|| ||\\//|| ||\\//||
The key components included in health/medical history
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Health/Medical History: ||\\//||
1. Medical diagnosis
||\\//|| ||\\//||
2. Previous physical examination findings
||\\//|| ||\\//|| ||\\//|| ||\\//||
3. History of symptoms
||\\//|| ||\\//|| ||\\//||
4. Recent illness, hospitalization, new medical diagnosis, or surgical procedures.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
5. Orthopedic problems
||\\//|| ||\\//||
6. Medication use and drug allergies
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
7. Other habits including caffeine, alcohol, tobacco use, or recreational drug use
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
8. Exercise history
||\\//|| ||\\//||
,9. Work history
||\\//|| ||\\//||
10. Family history of cardiac, pulmonary, or metabolic disease, stroke, or sudden death
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
The limitations of informed consent and health/medical history
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
1. Breach of contract claims
||\\//|| ||\\//|| ||\\//|| ||\\//||
2. Failure to obtain adequate informed consent
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
3. Negligence in procedural explanation
||\\//|| ||\\//|| ||\\//|| ||\\//||
4. Doesn't provide legal immunity
||\\//|| ||\\//|| ||\\//|| ||\\//||
5. Improper test administration
||\\//|| ||\\//|| ||\\//||
6. Personnel qualifications
||\\//|| ||\\//||
7. Poor safety procedures
||\\//|| ||\\//|| ||\\//||
8. Informed consent process can be used as defense
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
AGE
Men >_ 45 years old. Women >_ 55 years old
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
FAMILY HISTORY ||\\//||
Myocardial infarction, coronary revascularization, or sudden death before 55 years old in ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
father or other first degree male relative or before 65 years old in mother or other first
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
degree female relative ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
CIGARETTE SMOKER ||\\//||
Current cigarette smoker or those who quit within the previous 6 months or exposure to
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
environmental tobacco smoke ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
SEDENTARY LIFESTYLE ||\\//||
,Not participating in at least 30 min of moderate intensity physical activity on at least 3 days
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
of the week for at least 3 months.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
OBESITY
Body mass index >_ 30 kg/m2 ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or
waist girth >102 cm (40 in) for men and >88 cm (35 in) for women
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
HYPERTENSION
Systolic blood pressure >_ 140 mmHg and/or diastolic blood pressure >_ 90 mmHg, ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
confirmed by measurements of at least 2 separate occasions, ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or on anti-hypertensive medication.
||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
DYSLIPIDEMIA
low-density lipoprotein (LDL) cholesterol >_ 130 mg/dL ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or
high density lipoprotein (HDL) cholesterol < 40 mg/dL
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or
on lipid-lowering medication.
||\\//|| ||\\//||
, If total serum cholesterol is all that is available, use >_ 200 mgd/L
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
PREDIABETES
Prediabetes:
Impaired fasting glucose = fasting plasma glucose >_ 100 mg/dL and <_ 125 mg/dL
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or
impaired glucose tolerance (IGT) = 2 hours values in oral glucose tolerance test >_ 140
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
mg/dL and <_ 199 mg/dL confirmed by measurements on at least 2 separate occasions.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
NEGATIVE RISK FACTORS ||\\//|| ||\\//||
Negative risk factors: High density lipoprotein (HDL): >_ 60 mg/dL||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
The major signs or symptoms suggestive of cardiovascular, pulmonary and metabolic
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
disease.
1. Pain, discomfort in the chest, neck, jaw, arms, or other areas that may result from
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
ischemia.
2. Shortness of breath at rest or with mild exertion. Dyspnea.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
3. Dizziness or syncope
||\\//|| ||\\//|| ||\\//||
4. Orthopnea or paroxysmal nocturnal dyspnea
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
5. Ankle edema
||\\//|| ||\\//||
6. Palpitations or tachycardia
||\\//|| ||\\//|| ||\\//||
7. Intermittent claudication
||\\//|| ||\\//||
8. Known heart murmur
||\\//|| ||\\//|| ||\\//||
9. Unusual fatigue or shortness of breath with usual activities
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Cardiovascular risk factors or conditions that may require consultation with medical ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
personnel prior to exercise testing or training ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Exam with verified detailed solutions ||\\//|| ||\\//|| ||\\//|| ||\\//||
Pre-activity screening procedures and tools that provide accurate information about the ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
individual's health/medical history, current medical conditions, risk factors, ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
signs/symptoms of disease, current physical activity habits, and medications ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
1. Self-guided methods such as the Physical Activity Readiness Questionnaire (PAR-Q) or
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
the modified AHA/ACSM Health/Fitness Facility Preparticipation Screening Questionnaire.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
2. CVD risk factor assessment and classification by qualified health/fitness, clinical exercise,
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or health care professionals
||\\//|| ||\\//|| ||\\//|| ||\\//||
3. Medical evaluation including a physical examination and stress test by a qualified health
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
care provider. ||\\//||
The key components included in informed consent
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Informed Consent: ||\\//||
1. Purpose and explanation of the test
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
2. Attendant risks and discomforts
||\\//|| ||\\//|| ||\\//|| ||\\//||
3. Responsibilities of the participant
||\\//|| ||\\//|| ||\\//|| ||\\//||
4. Benefits to be expected
||\\//|| ||\\//|| ||\\//|| ||\\//||
5. Inquiries
||\\//||
6. Use of medical records
||\\//|| ||\\//|| ||\\//|| ||\\//||
7. Freedom of consent
||\\//|| ||\\//|| ||\\//||
The key components included in health/medical history
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Health/Medical History: ||\\//||
1. Medical diagnosis
||\\//|| ||\\//||
2. Previous physical examination findings
||\\//|| ||\\//|| ||\\//|| ||\\//||
3. History of symptoms
||\\//|| ||\\//|| ||\\//||
4. Recent illness, hospitalization, new medical diagnosis, or surgical procedures.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
5. Orthopedic problems
||\\//|| ||\\//||
6. Medication use and drug allergies
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
7. Other habits including caffeine, alcohol, tobacco use, or recreational drug use
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
8. Exercise history
||\\//|| ||\\//||
,9. Work history
||\\//|| ||\\//||
10. Family history of cardiac, pulmonary, or metabolic disease, stroke, or sudden death
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
The limitations of informed consent and health/medical history
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
1. Breach of contract claims
||\\//|| ||\\//|| ||\\//|| ||\\//||
2. Failure to obtain adequate informed consent
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
3. Negligence in procedural explanation
||\\//|| ||\\//|| ||\\//|| ||\\//||
4. Doesn't provide legal immunity
||\\//|| ||\\//|| ||\\//|| ||\\//||
5. Improper test administration
||\\//|| ||\\//|| ||\\//||
6. Personnel qualifications
||\\//|| ||\\//||
7. Poor safety procedures
||\\//|| ||\\//|| ||\\//||
8. Informed consent process can be used as defense
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
AGE
Men >_ 45 years old. Women >_ 55 years old
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
FAMILY HISTORY ||\\//||
Myocardial infarction, coronary revascularization, or sudden death before 55 years old in ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
father or other first degree male relative or before 65 years old in mother or other first
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
degree female relative ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
CIGARETTE SMOKER ||\\//||
Current cigarette smoker or those who quit within the previous 6 months or exposure to
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
environmental tobacco smoke ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
SEDENTARY LIFESTYLE ||\\//||
,Not participating in at least 30 min of moderate intensity physical activity on at least 3 days
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
of the week for at least 3 months.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
OBESITY
Body mass index >_ 30 kg/m2 ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or
waist girth >102 cm (40 in) for men and >88 cm (35 in) for women
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
HYPERTENSION
Systolic blood pressure >_ 140 mmHg and/or diastolic blood pressure >_ 90 mmHg, ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
confirmed by measurements of at least 2 separate occasions, ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or on anti-hypertensive medication.
||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
DYSLIPIDEMIA
low-density lipoprotein (LDL) cholesterol >_ 130 mg/dL ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or
high density lipoprotein (HDL) cholesterol < 40 mg/dL
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or
on lipid-lowering medication.
||\\//|| ||\\//||
, If total serum cholesterol is all that is available, use >_ 200 mgd/L
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
PREDIABETES
Prediabetes:
Impaired fasting glucose = fasting plasma glucose >_ 100 mg/dL and <_ 125 mg/dL
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
or
impaired glucose tolerance (IGT) = 2 hours values in oral glucose tolerance test >_ 140
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
mg/dL and <_ 199 mg/dL confirmed by measurements on at least 2 separate occasions.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Risk factor thresholds for ACSM risk stratification including genetic and lifestyle factors
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
related to the development of CVD ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
NEGATIVE RISK FACTORS ||\\//|| ||\\//||
Negative risk factors: High density lipoprotein (HDL): >_ 60 mg/dL||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
The major signs or symptoms suggestive of cardiovascular, pulmonary and metabolic
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
disease.
1. Pain, discomfort in the chest, neck, jaw, arms, or other areas that may result from
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
ischemia.
2. Shortness of breath at rest or with mild exertion. Dyspnea.
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
3. Dizziness or syncope
||\\//|| ||\\//|| ||\\//||
4. Orthopnea or paroxysmal nocturnal dyspnea
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
5. Ankle edema
||\\//|| ||\\//||
6. Palpitations or tachycardia
||\\//|| ||\\//|| ||\\//||
7. Intermittent claudication
||\\//|| ||\\//||
8. Known heart murmur
||\\//|| ||\\//|| ||\\//||
9. Unusual fatigue or shortness of breath with usual activities
||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
Cardiovascular risk factors or conditions that may require consultation with medical ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
personnel prior to exercise testing or training ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//|| ||\\//||
